tetano
Editor, Senior Moderator
Cell Rep
. 2021 Jul 10;109450.
doi: 10.1016/j.celrep.2021.109450. Online ahead of print.
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
David R Martinez[SUP] 1 [/SUP], Alexandra Schäfer[SUP] 2 [/SUP], Sarah R Leist[SUP] 2 [/SUP], Dapeng Li[SUP] 3 [/SUP], Kendra Gully[SUP] 2 [/SUP], Boyd Yount[SUP] 2 [/SUP], Joy Y Feng[SUP] 4 [/SUP], Elaine Bunyan[SUP] 4 [/SUP], Danielle P Porter[SUP] 4 [/SUP], Tomas Cihlar[SUP] 4 [/SUP], Stephanie A Montgomery[SUP] 5 [/SUP], Barton F Haynes[SUP] 3 [/SUP], Ralph S Baric[SUP] 2 [/SUP], Michel C Nussenzweig[SUP] 6 [/SUP], Timothy P Sheahan[SUP] 7 [/SUP]
Affiliations
Abstract
Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.
Keywords: B.1.351; COVID-19; RDV; SARS-CoV-2; monoclonal antibodies; remdesivir; th
. 2021 Jul 10;109450.
doi: 10.1016/j.celrep.2021.109450. Online ahead of print.
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
David R Martinez[SUP] 1 [/SUP], Alexandra Schäfer[SUP] 2 [/SUP], Sarah R Leist[SUP] 2 [/SUP], Dapeng Li[SUP] 3 [/SUP], Kendra Gully[SUP] 2 [/SUP], Boyd Yount[SUP] 2 [/SUP], Joy Y Feng[SUP] 4 [/SUP], Elaine Bunyan[SUP] 4 [/SUP], Danielle P Porter[SUP] 4 [/SUP], Tomas Cihlar[SUP] 4 [/SUP], Stephanie A Montgomery[SUP] 5 [/SUP], Barton F Haynes[SUP] 3 [/SUP], Ralph S Baric[SUP] 2 [/SUP], Michel C Nussenzweig[SUP] 6 [/SUP], Timothy P Sheahan[SUP] 7 [/SUP]
Affiliations
- PMID: 34289384
- DOI: 10.1016/j.celrep.2021.109450
Abstract
Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.
Keywords: B.1.351; COVID-19; RDV; SARS-CoV-2; monoclonal antibodies; remdesivir; th